Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197864 | 0.89 | NR1H4 (0.39) | NR1H4FFAR1PDE4APDE4BPDE4C | |
| SCHEMBL197119 | 0.77 | NR1H4 (0.59) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL198630 | 0.72 | CHEK2 (0.43) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL197876 | 0.72 | NR1H4 (0.60) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL197865 | 0.71 | NR1H4 (0.37) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL197499 | 0.70 | NR1H4 (0.58) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL197866 | 0.70 | NR1H4 (0.38) | NR1H4FFAR1CYP2C9KCNH2 | |
| SCHEMBL197650 | 0.69 | NR1H4 (0.60) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL197958 | 0.69 | NR1H4 (0.46) | NR1H4CYP2C9KCNH2 | |
| SCHEMBL197676 | 0.67 | NR1H4 (0.60) | NR1H4CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088930-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | NR1H4 292/4885FFAR1 328/4885PDE4A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.